Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems
June 20 2024 - 10:00AM
Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based
drug development company, announced the signing of a strategic
Memorandum of Understanding (MOU) with the global therapeutics
licensing and PR platform company, bioSeedin, a subsidiary of
ACROBiosystems.
Under this agreement, the two companies will
collaborate to leverage bioSeedin/ACROBiosystems' global network
for the promotion of Syntekabio's AI drug active compound database,
STB LaunchPad, as well as its AI-driven drug discovery
technologies. Given the synergies between the Syntekabio and
bioSeedin offerings, the companies will jointly seek pharmaceutical
clients for Syntekabio’s drug discovery technologies and compounds
and bioSeedin’s global therapeutics licensing and drug development
supporting network.
Jongsun Jung, PhD, CEO of Syntekabio, remarked,
“With our disease-agnostic STB LaunchPad platform, we have
successfully generated a wide range of hits, leads and compounds.
The extensive BioSeedin/ACROBiosystems global network should help
us significantly widen our range of potential customers and enable
us to secure contracts with pharmaceutical companies looking to
shorten drug development timelines by utilizing our active
compounds.”
Jenny Zhao, CEO of bioSeedin, stated, “We see
great synergies with Syntekabio’s AI capability and offerings and
can now provide customers a one-stop therapeutics licensing
solution to address several of their development needs. Early
feedback about this joint offering has been positive and we are
excited to move forward together to bring our programs and services
to even more pharmaceutical companies.”
STB LaunchPad is a database of active compounds
derived from Syntekabio's disease-agnostic synthetic drug candidate
discovery AI platform, DeepMatcher. It contains compounds targeting
over 130 proteins related to more than 15 diseases. This platform
allows for the initiation of drug development from the active
compound stage and enables the discovery of active compounds for
desired targets.
bioSeedin is a global asset transaction and
media platform that provides global therapeutics licensing
solutions through its network of over 7,000 pharmaceutical and
biotech companies across more than 70 countries. It is a subsidiary
of ACROBiosystems, a global drug development supplier and solution
provider of recombinant protein, reagents, analytical kits,
antibodies, and scientific services to pharmaceutical
companies.
About Syntekabio
Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug
discovery company bringing together biology and AI/ML since 2009
and facilitating the discovery of first-in-class and best-in-class
compounds, rapidly. The company has its own supercomputer cloud,
along with a global contract research organization network to
complement and validate its computational results. Syntekabio
offers clients a one-stop shop, with technologies and tailored
services to rapidly generate and optimize drug candidates from
target to IND-enabling. Syntekabio’s disease-agnostic platform
generates a continual stream of hits, leads, and drug candidates
that are readily available for purchase. The company also
undertakes client-specific projects to identify highly promising
development candidates for specific targets and indications. Visit
the Syntekabio website at www.syntekabio.com or follow the company
on LinkedIn for the latest updates.
Contact
Media inquiries – US &
Europe:
MC Services AGEurope: Dr. Cora Kaiser+49 89 210
228 0US: Laurie Doyle+1 339 832 0752
syntekabio@mc-services.eu